Several studies have shown that in patients with endocrine-sensitive or endocrine-resistant LBC, the addition of CDK4/6 inhibitors to endocrine therapy significantly prolongs progression-free survival. Here, CDK4 is linked to CDH1-related diffuse gastric and lobular breast cancer syndrome.